DAWN · Day One Biopharmaceuticals, Inc.
$21.53
+0.00 (+0.00%)
At close · Apr 24
Market Cap
$2.22B
Shares
103.33M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$158.18M
+20.6%
FY2025
Net Income
-$107.32B
-12.4%
FY2025
Operating Margin
-80.76%
+84.9pp
FY2025
Diluted EPS
-$1.04
-2%
FY2025
Operating Cash Flow
-$103.76M
-32.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|
| $225M – $250M | — | $158.18MG | $131.16M | $0 | $0 | — | — | — | |
| — | — | — | — | — | $4.75M | $4000 | -$30K | -$2.08M | |
| — | — | $148.14M | $227.7M | $130.52M | $85.62M | $43.58M | $9.1M | $13.9M | |
| — | — | $120.59M | $115.45M | $75.54M | $61.29M | $29.16M | $4.68M | $1.01M | |
| — | — | $3.11M | $1.47M | $0 | $0 | — | — | — | |
| — | — | $366K | $92K | $36K | $63K | $20K | $16K | $0 | |
| — | — | $285.93M | $348.43M | $206.06M | $146.91M | $72.74M | $13.78M | $14.91M | |
| — | — | -$127.75M | -$217.27M | -$206.06M | -$146.91M | -$72.74M | -$13.78M | -$14.91M | |
| — | — | -80.76% | -165.65% | — | — | — | — | — | |
| — | — | -$127.38M | -$217.18M | -$206.03M | -$146.85M | -$72.72M | -$13.77M | -$14.91M | |
| — | — | $18.45M | $128.92M | $17.15M | $4.73M | -$15K | -$31K | -$2000 | |
| — | — | -$1.98M | $7.14M | $0 | $0 | — | — | — | |
| — | — | -$107.32B | -$95.5B | -$188.92B | -$142.18B | -$72.75B | -$40.51M | -$12.63M | |
| — | — | -67847.16% | -72808.23% | — | — | — | — | — | |
| — | — | — | — | $0 | $0 | -$2.11M | -$3.34M | -$4.35M | |
| — | -$208.94M | — | — | -$188.92M | -$142.18M | -$70.65M | — | — | |
| — | — | -$107.34M | -$95.42M | -$188.84M | -$142.25M | -$72.75M | -$43.84M | — | |
| USD/shares | — | — | -$1.04 | -$1.02 | -$2.37 | -$2.17 | -$4.62 | -$7.33 | — |
| USD/shares | — | — | -$1.04 | -$1.02 | -$2.37 | -$2.17 | -$4.62 | -$7.33 | — |
| shares | — | — | 103.21M | 93.23M | 79.77M | 65.47M | 36.96M | 5.53M | 5.92M |
| shares | — | — | 103.21M | 93.23M | 79.77M | 65.47M | 36.96M | 5.53M | 5.92M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 6.32×
EV/EBIT
—
Peer median 17.62×
P/E (TTM)
—
Peer median 16.55×
Peer medians compare against the 245 similar-size Biotechnology companies (of 522 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Product | $155,421,000 | $57,217,000 | $0 | $0 |
| License | $2,761,000 | $73,944,000 | $0 | $0 |